BeOne Medicines (ONC) Competitors $310.81 +0.78 (+0.25%) As of 10/24/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONC vs. SNY, GSK, ARGX, TAK, INSM, BNTX, TEVA, GMAB, SMMT, and ASNDShould you be buying BeOne Medicines stock or one of its competitors? The main competitors of BeOne Medicines include Sanofi (SNY), GSK (GSK), argenex (ARGX), Takeda Pharmaceutical (TAK), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. BeOne Medicines vs. Its Competitors Sanofi GSK argenex Takeda Pharmaceutical Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S BeOne Medicines (NASDAQ:ONC) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation. Which has higher valuation & earnings, ONC or SNY? Sanofi has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeOne Medicines$3.81B8.94-$644.79M-$1.73-179.66Sanofi$44.46B2.85$6.02B$4.1612.41 Does the media prefer ONC or SNY? In the previous week, Sanofi had 14 more articles in the media than BeOne Medicines. MarketBeat recorded 25 mentions for Sanofi and 11 mentions for BeOne Medicines. Sanofi's average media sentiment score of 0.94 beat BeOne Medicines' score of 0.83 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 13 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ONC or SNY? BeOne Medicines has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Do analysts recommend ONC or SNY? BeOne Medicines currently has a consensus target price of $345.60, indicating a potential upside of 11.19%. Sanofi has a consensus target price of $62.67, indicating a potential upside of 21.35%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90Sanofi 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in ONC or SNY? 48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 6.6% of BeOne Medicines shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is ONC or SNY more profitable? Sanofi has a net margin of 21.47% compared to BeOne Medicines' net margin of -3.89%. Sanofi's return on equity of 16.86% beat BeOne Medicines' return on equity.Company Net Margins Return on Equity Return on Assets BeOne Medicines-3.89% -1.22% -0.72% Sanofi 21.47%16.86%9.63% SummarySanofi beats BeOne Medicines on 12 of the 16 factors compared between the two stocks. Get BeOne Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricBeOne MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.06B$3.02B$6.24B$10.69BDividend YieldN/A57.75%5.72%4.81%P/E RatioN/A27.9431.4730.88Price / Sales8.94612.98564.64176.26Price / CashN/A168.3237.0861.44Price / Book9.115.6512.056.61Net Income-$644.79M$33.06M$3.33B$277.10M7 Day Performance-1.77%3.16%1.93%2.56%1 Month Performance-5.45%8.14%7.77%3.77%1 Year PerformanceN/A-2.49%56.40%33.01% BeOne Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCBeOne Medicines3.0023 of 5 stars$310.81+0.3%$345.60+11.2%N/A$34.06B$3.81B0.0011,000Positive NewsAnalyst ForecastSNYSanofi4.2703 of 5 stars$50.62+1.2%$62.67+23.8%-0.8%$122.82B$44.46B12.1782,878Trending NewsEarnings ReportGap UpGSKGSK1.8588 of 5 stars$43.92+0.3%$37.38-14.9%+14.5%$88.97B$40.10B20.3368,629News CoverageUpcoming EarningsDividend CutOptions VolumeGap DownARGXargenex2.6836 of 5 stars$843.66+0.8%$817.53-3.1%+48.3%$51.24B$2.25B43.261,599Upcoming EarningsAnalyst DowngradeTAKTakeda Pharmaceutical3.2569 of 5 stars$14.05+1.2%N/A+1.7%$44.17B$30.09B46.8347,455News CoverageUpcoming EarningsINSMInsmed3.062 of 5 stars$165.76+1.6%$152.88-7.8%+122.6%$34.49B$398.11M-29.031,271Upcoming EarningsAnalyst ForecastBNTXBioNTech2.5779 of 5 stars$105.14+0.1%$134.32+27.8%-5.4%$25.26B$2.98B-65.716,772News CoverageAnalyst ForecastTEVATeva Pharmaceutical Industries3.633 of 5 stars$19.33-1.5%$25.57+32.3%+3.8%$22.51B$16.54B-120.8136,830Analyst ForecastGMABGenmab A/S3.816 of 5 stars$33.17+1.3%$40.80+23.0%+31.0%$21.03B$3.12B16.672,682Analyst ForecastShort Interest ↑Analyst RevisionSMMTSummit Therapeutics2.796 of 5 stars$20.99-4.5%$31.29+49.1%-0.9%$16.32BN/A-20.78110Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionGap UpASNDAscendis Pharma A/S2.7579 of 5 stars$210.50+1.7%$249.80+18.7%+55.6%$12.77B$393.54M-40.791,017Analyst Forecast Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives ARGX Alternatives TAK Alternatives INSM Alternatives BNTX Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives ASND Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONC) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeOne Medicines Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BeOne Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONC Stock Alerts